Cite
HARVARD Citation
Fasching, P. et al. (n.d.). 282TiPReal-world effectiveness of ribociclib + aromatase inhibitor, or endocrine monotherapy, or chemotherapy as first-line treatment in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: The RIBANNA study. Annals of oncology. p. . [Online].